Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Crossover Study to Investigate the Bronchodilatation Post-inhalation of GSK961081 Alone and With the Addition of Cumulative Doses of Short Acting Bronchodilators (Salbutamol and Ipratropium Bromide) in Patients With COPD
Conditions
Interventions
400 microgrammes GSK961081
1200 microgrammes GSK961081
Locations
4
New Zealand
GSK Investigational Site
Wellington, New Zealand
GSK Investigational Site
Chiang Mai, Thailand
GSK Investigational Site
Khon Kaen, Thailand
GSK Investigational Site
Manchester, United Kingdom
Start Date
April 1, 2008
Primary Completion Date
October 1, 2008
Completion Date
October 19, 2008
Last Updated
October 20, 2021
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
Theravance Biopharma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions